EMA AI reflection paper and its 4 linked instruments
How to read this page
- First column: EMA AI reflection paper. The others are every document linked to it.
- Scroll sideways if there are more columns than fit.
- It does not compare content. It does not say which is stricter. Read the official texts for that.
| EMA AI reflection paper | ICH E6(R3) GCP | ICH Q9(R1) | ICH Q10 | HMA-EMA AI workplan | |
|---|---|---|---|---|---|
| Authority | EMA | ICH | ICH | ICH | EMA |
| Legal weight | Guidance & Q&A | Guidance & Q&A | Guidance & Q&A | Guidance & Q&A | Guidance & Q&A |
| Status | Final | Final | Final | Final | Final |
| Last verified | Not yet | Not yet | Not yet | Not yet | Not yet |
| Summary | EMA's current thinking on AI and machine learning for human and veterinary medicines, covering principles that apply at any stage of a medicine's lifecycle, from drug discovery to after authorisation. | Revised ICH guideline on good clinical practice. FDA says it adds flexible, risk-based approaches and embraces innovations in trial design, conduct and technology. | The international guideline on quality risk management. It is the basis for scaling validation effort to risk in Annex 11, Annex 22 and computer software assurance, and the 2023 revision addresses subjectivity, formality and risk-based decision-making. | ICH model for an effective quality management system for the pharmaceutical industry. | Joint HMA and EMA workplan for artificial intelligence in medicines regulation, 2023 to 2028. It is a plan, not a requirement. |
| Lifecycle |
|
|
|
|
|
| Source | Official text Source: EMA. | Official text Source: ICH. | Official text Source: ICH. | Official text Source: ICH. | Official text Source: EMA. |
These facts are placed side by side from each record. This page does not say which is stricter or whether requirements differ. Read the official texts.